AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM
ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the
CEO
Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, discussed the Company’s recent news release regarding top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent
ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
Lesen Sie auch
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.
The Company’s lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in
clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com